The trend of weight loss drug sector in US stock market is diverging. Novo Nordisk (NVO.US) and Eli Lilly and Co (LLY.US) face challenges to their duopoly.

As more and more pharmaceutical companies enter the lucrative weight loss drug market to get a share of the pie, the increasing competition is making investors worried about the duopoly position of Novo Nordisk and Eli Lilly and Co in this market.

Zhitong Finance06:50 ET

Roche Obesity-pill Trial Results Weigh on Shares of Eli Lilly, Novo Nordisk

Shares of weight-loss drugmakers including Eli Lilly & Co., Novo Nordisk A/S and Structure Therapeutics Inc. fell on Wednesday after Roche Holding AG announced positive early-stage trial data for its experimental obesity pill.

MarketWatchJul 17 12:54 ET

Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, Altimmune (NASDAQ:ALT) shareholders have done very

Simply Wall StJul 15 09:39 ET

B.Riley Financial Maintains Altimmune(ALT.US) With Buy Rating

B.Riley Financial analyst Mayank Mamtani maintains $Altimmune(ALT.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 27.8% and a total average return of -16.5% over

Moomoo NewsJul 12 11:31 ET · Ratings

These Are the Weight Loss Drug Stocks With the Most Upside - SA Sentiment Survey

Seeking AlphaJul 12 10:50 ET

This Weight Loss Stock Is the Best Alternative to Eli Lilly, Novo - SA Sentiment

Seeking AlphaJul 12 04:12 ET